Open AccessPhase II trial of an AKT inhibitor (perifosine) for recurrent glioblastoma
Author(s) -
Thomas Kaley,
Katherine S. Panageas,
Ingo K. Mellinghoff,
Craig Nolan,
Igor T. Gavrilovic,
Lisa M. DeAngelis,
Lauren E. Abrey,
Eric C. Holland,
Andrew B. Lassman
Publication year - 2019
Publication title -
journal of neuro-oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.256
H-Index - 114
eISSN - 1573-7373
pISSN - 0167-594X
DOI - 10.1007/s11060-019-03243-7
Subject(s) - discontinuation , medicine , tolerability , oncology , clinical endpoint , toxicity , radiation therapy , phases of clinical research , nausea , clinical trial , neutropenia , surgery , adverse effect
Perifosine (PRF) is an oral alkylphospholipid with antineoplastic effects and reasonable tolerability. It inhibits signaling through the PI3/AKT axis and other cascades of biologic importance in glioblastoma, and has promising pre-clinical activity in vitro and in vivo. Therefore, we conducted a phase II open-label single-arm clinical trial of perifosine for patients with recurrent glioblastoma (GBM).